Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Remodulin (including Remunity Pump) sales rose 17% year over year to $134.5 million due to higher volume growth in the United States. Sales of Orenitram rose 28% year over year to $107.8 million ...